Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a report released on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The company has a market capitalization of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 1 year low of $0.01 and a 1 year high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.